Right ventricular expression of NT-proBNP adds predictive value to REVEAL score in patients with pulmonary arterial hypertension

doi:10.1002/ehf2.13410

CNU IR > College of Smart Living > Dept. of Hospital and Health (including master's program) > Periodical Articles > Item 310902800/34426

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34426

Title:	Right ventricular expression of NT-proBNP adds predictive value to REVEAL score in patients with pulmonary arterial hypertension
Authors:	Chang, Wei-Ting Shih, Jhih-Yuan Hong, Chon-Seng Lin, Yu-Wen Chen, Yi-Chen Ho, Chung-Han Chen, Zhih-Cherng Roan, Jun-Neng Hsu, Chih-Hsin
Contributors:	Chi Mei Med Ctr, Div Cardiol, Dept Internal Med Southern Taiwan Univ Sci & Technol, Dept Biotechnol Natl Cheng Kung Univ, Inst Clin Med, Coll Med Chi Mei Med Ctr, Dept Med Res Chia Nan Univ Pharm & Sci, Dept Hosp & Hlth Care Adm Natl Cheng Kung Univ Hosp, Div Cardiovasc Surg, Dept Surg Natl Cheng Kung Univ, Coll Med Natl Cheng Kung Univ, Med Device Innovat Ctr Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Dept Internal Med, Coll Med Natl Cheng Kung Univ Hosp, Dou Liou Branch, Dept Internal Med Kaohsiung Med Univ, Coll Med, Dept Resp Therapy
Keywords:	NT-proBNP RV expression HF hospitalization Group I PAH
Date:	2021
Issue Date:	2023-11-11 11:52:05 (UTC+8)
Publisher:	WILEY PERIODICALS, INC
Abstract:	Aims The Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) risk scores differentiate survivals in patients with pulmonary arterial hypertension (PAH). However, measurements of N-terminal pro B-type natriuretic peptide (NT-proBNP) in the peripheral blood may not adequately reflect early-stage decompensated heart failure (HF). Given that right heart catheterization (RHC) can facilitate measurements of intracardiac NT-proBNP, in this study our aim was to evaluate the predictive role of right ventricular (RV) NT-proBNP measurements in patients with PAH. Methods and results We prospectively collected intracardiac blood samples for NT-proBNP measurements from patients diagnosed with World Health Organization Group I PAH during RHC. Clinical information including the aetiology of PAH (idiopathic, connective tissue disease, or congenital heart disease) and REVEAL scores were recorded. The primary endpoint was hospitalization for decompensated HF; median duration of follow-up was 28 months. Among the 62 patients evaluated, 12 reached the designated endpoint. REVEAL risk scores were higher among patients hospitalized for HF. We detected no significant differences in plasma NT-proBNP levels in peripheral circulation, in the right atrium, or in pulmonary arterial blood; however, significantly higher levels of NT-proBNP were detected in the RV in patients diagnosed with PAH. RV NT-proBNP was a sensitive predictor (cut-off value 1500 pg/mL) of subsequent hospitalization for HF. Our findings indicate that RV NT-proBNP levels add predictive value to REVEAL scores with respect to future hospitalization due to HF. Conclusions Right ventricular NT-proBNP levels combined with REVEAL 2.0 could predict the development of subsequent HF in patients with PAH and may be a potential biomarker.
Relation:	ESC HEART FAIL, v.8, n.4, pp.3082-3092
Appears in Collections:	[Dept. of Hospital and Health (including master's program)] Periodical Articles

Files in This Item:

File	Description	Size	Format
ehf2.13410.pdf		4820Kb	Adobe PDF	102	View/Open
index.html		0Kb	HTML	248	View/Open

Loading...